```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssptasjl1626

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 08:06:30 ON 05 JUN 2007
FILE 'CAPLUS' ENTERED AT 08:06:30 ON 05 JUN 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    32.09     223.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -4.68      -4.68

=> d his

     (FILE 'HOME' ENTERED AT 06:35:08 ON 05 JUN 2007)

     FILE 'CAPLUS' ENTERED AT 06:36:30 ON 05 JUN 2007
L1             1 S US200!-510907/APPS

     FILE 'REGISTRY' ENTERED AT 06:36:36 ON 05 JUN 2007

     FILE 'CAPLUS' ENTERED AT 06:36:39 ON 05 JUN 2007
L2               TRA L1 1- RN :       274 TERMS

     FILE 'REGISTRY' ENTERED AT 06:36:39 ON 05 JUN 2007
L3           274 SEA L2

     FILE 'REGISTRY' ENTERED AT 08:04:37 ON 05 JUN 2007
L4               STRUCTURE UPLOADED
L5             1 S L4
L6            66 S L4 SSS FULL

     FILE 'CAPLUS' ENTERED AT 08:05:48 ON 05 JUN 2007
L7             6 S L6

=> d l4
L4 HAS NO ANSWERS
L4                STR
```




```
G1 O,N


Structure attributes must be viewed using STN Express query preparation.
```

> d l7 tot bib abs hitstr

L7 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:874421 CAPLUS <<LOGINID::20070605>>
DN 145:376982
TI Solid-phase synthesis and structure-activity relationships of novel biarylethers as melanin-concentrating hormone receptor-1 antagonists
AU Ma, Vu; Bannon, Anthony W.; Baumgartner, Jamie; Hale, Clarence; Hsieh, Faye; Hulme, Christopher; Rorrer, Kirk; Salon, John; van Staden, Carlo; Tempest, Paul
CS Chemistry Research and Discovery, Amgen Inc., Thousand Oaks, CA, 91320, USA
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(19), 5066-5072
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Ltd.
DT Journal
LA English
AB Melanin-concentrating hormone (MCH) is a cyclic 19 amino acid orexigenic neuropeptide. The action of MCH on feeding is thought to involve the activation of its resp. G protein-coupled receptor MCH-R1. Consequently, antagonists that block MCH regulated MCH-R1 activity may provide a viable approach to the treatment of diet-induced obesity. This communication reports the discovery of a novel MCH-R1 receptor antagonist, which was identified through high throughput screening. The solid-phase synthesis and structure-activity relationship of related analogs is described.
IT 846020-68-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(solid phase synthesis and structure-activity relationships of biarylethers as melanin-concentrating hormone receptor-1 antagonists identified through high throughput screening)
RN 846020-68-6 CAPLUS
CN Benzamide, 4-(3,4-dimethylphenoxy)-3-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:315070 CAPLUS <<LOGINID::20070605>>
DN 145:285
TI Identification of 4-amino-2-cyclohexylaminoquinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists
AU Kanuma, Kosuke; Omodera, Katsunori; Nishiguchi, Mariko; Funakoshi, Takeo; Chaki, Shigeyuki; Nagase, Yasuko; Iida, Izumi; Yamaguchi, Jun-ichi; Semple, Graeme; Tran, Thuy-Anh; Sekiguchi, Yoshinori
CS Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd, Saitama, Saitama, 331-9530, Japan
SO Bioorganic & Medicinal Chemistry (2006), 14(10), 3307-3319
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier B.V.
DT Journal
LA English
AB The optimization of the distance between two key pharmacophore features within our first hit compds. led to the identification of a new class of potent non-peptidic antagonists for the MCH-R1, based around 4-amino-2-cyclohexylaminoquinazolines. In particular, ATC0065, N 2-[cis-4-({2-[4-Bromo-2-(trifluoromethoxy)phenyl]ethyl}amino)cyclohexyl]-N4,N4-dimethylquinazoline-2,4-diamine dihydrochloride, bound with high affinity to the MCH-R1 (IC50 value of 16 nM) and showed good metabolic stability in liver microsomes from human and rat.
IT 617245-27-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino cyclohexylaminoquinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists)
RN 617245-27-9 CAPLUS
CN Benzamide, 2-methoxy-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:182684 CAPLUS <<LOGINID::20070605>>
DN 142:254663
TI Amine-containing phenyl derivative melanin-concentrating hormone receptor antagonists for therapeutic use

IN Tempest, Paul; Hulme, Christopher; Ma, Vu
PA Amgen, Inc., USA
SO PCT Int. Appl., 319 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005019240	A2	20050303	WO 2004-US25970	20040811
	WO 2005019240	A3	20050506		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004266228	A2	20050303	AU 2004-266228	20040811
	AU 2004266228	A1	20050303		
	CA 2534428	A1	20050303	CA 2004-2534428	20040811
	US 2005256161	A1	20051117	US 2004-916219	20040811
	EP 1654225	A2	20060510	EP 2004-780754	20040811
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007502283	T	20070208	JP 2006-523322	20040811
PRAI	US 2003-494855P	P	20030813		
	WO 2004-US25970	W	20040811		

OS MARPAT 142:254663
GI



I

AB The title compds., or pharmaceutically-acceptable salts, tautomers or prodrugs thereof, are provided. Also provided are methods for treating or preventing a melanin-concentrating hormone-mediated disorder in a subject, comprising administering to a subject in need of such treatment or prevention a compound of the invention. Preparation of compds, e.g. I, is

described.

IT 846020-68-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amine-containing Ph derivative melanin-concentrating hormone receptor antagonists for therapeutic use)

RN 846020-68-6 CAPLUS

CN Benzamide, 4-(3,4-dimethylphenoxy)-3-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L7 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:767279 CAPLUS <<LOGINID::20070605>>

DN 141:405643

TI 4-Acylamino-and 4-ureidobenzamides as melanin-concentrating hormone (MCH) receptor 1 antagonists

AU Receveur, Jean-Marie; Bjurling, Emelie; Ulven, Trond; Little, Paul Brian; Norregaard, Pia K.; Hoegberg, Thomas

CS 7TM Pharma A/S, Horsholm, DK-2970, Den.

SO Bioorganic & Medicinal Chemistry Letters (2004), 14(20), 5075-5080
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier B.V.

DT Journal
LA English
OS CASREACT 141:405643
AB Synthesis, in vitro biol. evaluation and structure-activity relationships of 4-acylamino-and 4-ureidobenzamides as novel hMCH1R-antagonists are disclosed. The nature of the amine side chains could be varied considerably in contrast to the central benzamide scaffold and aromatic substituents.
IT 617244-46-9 617244-63-0 617245-16-6
617245-17-7 617245-26-8 617245-27-9
617245-56-4 617245-67-7 617246-05-6
617246-53-4 617246-60-3 791613-58-6
791613-65-5 791613-66-6 791613-67-7
791613-69-9
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(4-Acylamino-and 4-ureidobenzamides as melanin-concentrating hormone (MCH) receptor 1 antagonists)
RN 617244-46-9 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617244-63-0 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-4-[methyl[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-16-6 CAPLUS
CN Benzamide, 2-methoxy-4-[[[[4-(phenylamino)phenyl]amino]carbonyl]amino]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 617245-17-7 CAPLUS
CN Benzamide, 2-methoxy-4-[[[[3-(phenylamino)phenyl]amino]carbonyl]amino]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 617245-26-8 CAPLUS
CN Benzamide, 2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 617245-27-9 CAPLUS
CN Benzamide, 2-methoxy-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 617245-56-4 CAPLUS
CN Benzamide, 2-methoxy-N-[3-(4-morpholinyl)propyl]-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-67-7 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-2-ethoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617246-05-6 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-4-[[[methyl(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617246-53-4 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617246-60-3 CAPLUS
CN Benzamide, 4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 791613-58-6 CAPLUS
CN Benzamide, 2-methoxy-4-[[[(2-phenoxyphenyl)amino]carbonyl]amino]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 791613-65-5 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-4-[methyl[[methyl(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 791613-66-6 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-N-methyl-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 791613-67-7 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-N-methyl-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 791613-69-9 CAPLUS
CN Benzamide, 5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:837035 CAPLUS <<LOGINID::20070605>>
DN 139:337787
TI Preparation of novel methoxybenzamides for use in MCH receptor related disorders

IN Hoegberg, Thomas; Bjurling, Anna Emelie; Receveur, Jean-Marie; Little, Paul Brian; Elling, Christian E.; Norregaard, Pia Karina; Ulven, Trond

PA 7TM Pharma A/S, Den.

SO PCT Int. Appl., 133 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003087045	A1	20031023	WO 2003-DK231	20030408
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2482341	A1	20031023	CA 2003-2482341	20030408
	AU 2003226926	A1	20031027	AU 2003-226926	20030408
	EP 1497260	A1	20050119	EP 2003-746255	20030408
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2006235035	A1	20061019	US 2005-510907	20050516
PRAI	DK 2002-519	A	20020409		
	DK 2002-520	A	20020409		
	DK 2002-524	A	20020409		
	DK 2002-1818	A	20021125		
	WO 2003-DK231	W	20030408		

OS MARPAT 139:337787

GI



I



II

AB Title compds. I [wherein A = a linker, e.g. CHR7CONR7, CONR7, OCONR7, SO2NR7, CHR7NR7CO, NR7COR7, hexahydro-2-oxo-pyrimidine-1,3-diyl, 2-oxoimidazolidine-1,3-diyl, 1,2,4-oxadiazolediyl, 1,3,4-oxadiazolediyl, CH=CH, OCHR7, NR7CHR7, SCHR7, or (un)substituted imidazolediyl or 1,2,4-triazolediyl; Ar = independently (hetero)aryl; R1 = alkoxy; R2 = H, OH, NH2, or alkoxy; COQ = amino-substituted amide; R5 and R6 = independently H, halo, alkoxy, OH, (di)alkylamino, hydroxyalkyl,

carboxamido, acyl(amido), CHO, nitrile, alkyl, alkenyl, alkynyl, SMe, (fluoro)alkyl, (fluoro)alkoxy, (fluoro)thioalkoxy, SO2NH2, (di)alkylaminosulfonyl, or alkylsulfonyl; R7 = independently H, alkyl, or alkenyl; R8 = halo, (alkyl)(cyclo)alkyl, alkenyl, alkynyl, (alkyl)(hetero)aryl, (alkyl)heterocyclyl, (aryl)alkoxy, aryloxy, dialkylamino, (di)alkylcarbamoyl, (di)arylcarbamoyl, alkanoyl(amino), aroyl(amino), SMe, (fluoro)alkyl, (fluoro)alkoxy, (fluoro)thioalkoxy, or R6ArB; B = a single bond or connecting moiety; X = H, halo, SMe, CF3, OCF3, SCF3, OMe, alkyl, or alkenyl; and physiol. acceptable salts, complexes, solvates, and prodrugs thereof] were prepared as melanin-concentrating hormone (MCH) receptor modulators. For example, coupling of procainamide with 4-trifluoromethoxyphenyl isocyanate in the presence of TEA in CH2Cl2 gave II (59%). In assays of [125I]-MCH binding and phosphatidylinositol turnover using transiently transfected COS-7 cells or stably transfected CHO cells expressing the human MCH-1 receptor, II exhibited activity with IC50 values of 0.07 μM and 0.29 μM, resp. Administration of II (10 mg/kg i.p.) to male Sprague Dawley rats resulted in a significant reduction of their cumulative food intake over 6 h. Thus, I and their pharmaceutical compns. are useful in the treatment or prevention of obesity, depression, diabetes, bulimia, and other MCH receptor related disorders (no data).

IT 617245-28-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(MCH receptor modulator; preparation of methoxybenzamides as MCH receptor modulators for treatment of obesity, depression, diabetes, bulimia, and related disorders)

RN 617245-28-0 CAPLUS

CN Benzamide, 4-[[[[3-(4-fluorophenoxy)phenyl]amino]carbonyl]amino]-2-methoxy-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



IT 617244-39-0P 617244-42-5P 617244-43-6P
617244-44-7P 617244-45-8P 617244-46-9P
617244-48-1P 617244-52-7P 617244-53-8P
617244-54-9P 617244-55-0P 617244-56-1P
617244-58-3P 617244-63-0P 617245-16-6P
617245-17-7P 617245-18-8P 617245-20-2P
617245-22-4P 617245-24-6P 617245-25-7P
617245-26-8P 617245-27-9P 617245-29-1P
617245-30-4P 617245-32-6P 617245-33-7P
617245-39-3P 617245-41-7P 617245-42-8P
617245-45-1P 617245-46-2P 617245-48-4P
617245-50-8P 617245-51-9P 617245-52-0P
617245-53-1P 617245-56-4P 617245-57-5P
617245-58-6P 617245-59-7P 617245-67-7P
617245-69-9P 617245-70-2P 617245-72-4P
617245-87-1P 617246-05-6P 617246-06-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MCH receptor modulator; preparation of methoxybenzamides as MCH receptor modulators for treatment of obesity, depression, diabetes, bulimia, and related disorders)

RN 617244-39-0 CAPLUS
CN Benzamide, N-[2-(dimethylamino)ethyl]-2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617244-42-5 CAPLUS
CN Benzamide, 2-methoxy-N-[3-(4-methyl-1-piperazinyl)propyl]-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617244-43-6 CAPLUS
CN Benzamide, 2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)





RN 617244-44-7 CAPLUS
CN Benzamide, 2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 617244-45-8 CAPLUS
CN Benzamide, 2-methoxy-N-[2-(4-morpholinyl)ethyl]-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617244-46-9 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617244-48-1 CAPLUS
CN Benzamide, N-[2-[bis(1-methylethyl)amino]ethyl]-2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617244-52-7 CAPLUS
CN Benzamide, N-[2-(diethylamino)-1-methylethyl]-2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617244-53-8 CAPLUS
CN Benzamide, 2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 617244-54-9 CAPLUS
CN Benzamide, 2-methoxy-N-[3-(4-morpholinyl)propyl]-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617244-55-0 CAPLUS
CN Benzamide, 2-methoxy-N-[3-(2-methyl-1-piperidinyl)propyl]-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617244-56-1 CAPLUS
CN Benzamide, N-[3-(diethylamino)propyl]-2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617244-58-3 CAPLUS
CN Benzamide, N-[3-(dibutylamino)propyl]-2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617244-63-0 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-4-[methyl[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-16-6 CAPLUS
CN Benzamide, 2-methoxy-4-[[[[4-(phenylamino)phenyl]amino]carbonyl]amino]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 617245-17-7 CAPLUS
CN Benzamide, 2-methoxy-4-[[[[3-(phenylamino)phenyl]amino]carbonyl]amino]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 617245-18-8 CAPLUS
CN Benzamide, 2-methoxy-N-[3-(1-piperidinyl)propyl]-4-[[[[4-[[3-(trifluoromethoxy)phenyl]amino]phenyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 617245-20-2 CAPLUS
CN Benzamide, 2-methoxy-N-[3-(1-piperidinyl)propyl]-4-[[[[4-[[4-(trifluoromethoxy)phenyl]amino]phenyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 617245-22-4 CAPLUS
CN Benzamide, 2-methoxy-N-[3-(1-piperidinyl)propyl]-4-[[[[3-[[3-(trifluoromethoxy)phenyl]amino]phenyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 617245-24-6 CAPLUS
CN Benzamide, 2-methoxy-4-[[[[3-[(4-methoxyphenyl)amino]phenyl]amino]carbonyl]amino]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 617245-25-7 CAPLUS
CN Benzamide, 2-methoxy-N-[3-(1-piperidinyl)propyl]-4-[[[[3-[[4-(trifluoromethyl)phenyl]amino]phenyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-26-8 CAPLUS
CN Benzamide, 2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 617245-27-9 CAPLUS
CN Benzamide, 2-methoxy-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 617245-29-1 CAPLUS
CN Benzamide, 2-methoxy-N-[3-(1-piperidinyl)propyl]-4-[[[[4-[4-(trifluoromethyl)phenoxy]phenyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-30-4 CAPLUS
CN Benzamide, 2-methoxy-N-[3-(1-piperidinyl)propyl]-4-[[[[4-[4-(trifluoromethoxy)phenoxy]phenyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-32-6 CAPLUS
CN Benzamide, 2-methoxy-N-[3-(1-piperidinyl)propyl]-4-[[[[3-[3-(trifluoromethyl)phenoxy]phenyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-33-7 CAPLUS
CN Benzamide, 2-methoxy-N-[3-(1-piperidinyl)propyl]-4-[[[[4-[3-(trifluoromethoxy)phenoxy]phenyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-39-3 CAPLUS
CN Benzamide, 2-methoxy-N-[2-(4-morpholinyl)ethyl]-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-41-7 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-42-8 CAPLUS
CN Benzamide, 2-methoxy-N-[3-[methyl(1-methylethyl)amino]propyl]-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-45-1 CAPLUS
CN Benzamide, 2-methoxy-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 617245-46-2 CAPLUS
CN Benzamide, N-[2-(dimethylamino)ethyl]-2-methoxy-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-48-4 CAPLUS
CN Benzamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-2-methoxy-4-[[[(3-

phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-50-8 CAPLUS
CN Benzamide, 2-methoxy-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 617245-51-9 CAPLUS
CN Benzamide, N-[2-(diethylamino)-1-methylethyl]-2-methoxy-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-52-0 CAPLUS
CN Benzamide, N-[3-(dimethylamino)propyl]-2-methoxy-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-53-1 CAPLUS
CN Benzamide, 2-methoxy-N-[3-(4-methyl-1-piperazinyl)propyl]-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-56-4 CAPLUS
CN Benzamide, 2-methoxy-N-[3-(4-morpholinyl)propyl]-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-57-5 CAPLUS
CN Benzamide, 2-methoxy-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]-N-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)





RN 617245-58-6 CAPLUS
CN Benzamide, N-[3-(diethylamino)propyl]-2-methoxy-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-59-7 CAPLUS
CN Benzamide, N-[4-(dimethylamino)butyl]-2-methoxy-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-67-7 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-2-ethoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-69-9 CAPLUS
CN Benzamide, N-[3-(dibutylamino)propyl]-2-methoxy-4-[methyl[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-70-2 CAPLUS
CN Benzamide, 4-[[[[4-(4-fluorophenoxy)phenyl]amino]carbonyl]amino]-2-methoxy-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 617245-72-4 CAPLUS
CN Benzamide, 2-methoxy-N-[3-(4-morpholinyl)propyl]-4-[[[[4-[[4-(trifluoromethyl)phenyl]amino]phenyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617245-87-1 CAPLUS
CN Benzamide, 2-methoxy-N-[3-[(1-methylethyl)(phenylmethyl)amino]propyl]-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617246-05-6 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-4-[[[methyl(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617246-06-7 CAPLUS
CN Benzamide, 2-methoxy-4-[[[methyl(4-phenoxyphenyl)amino]carbonyl]amino]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



IT 617246-16-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of methoxybenzamides as MCH receptor modulators for treatment of obesity, depression, diabetes, bulimia, and related disorders)
RN 617246-16-9 CAPLUS
CN Benzamide, 5-fluoro-2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:837034 CAPLUS <<LOGINID::20070605>>
DN 139:337786
TI Preparation of novel benzamides for use in MCH receptor related disorders
IN Ulven, Trond; Hoegberg, Thomas; Elling, Christian E.; Norregaard, Pia Karina; Bjurling, Anna Emelie; Receveur, Jean-Marie; Little, Paul Brian
PA 7TM Pharma A/S, Den.
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003087044	A2	20031023	WO 2003-DK232	20030408
	WO 2003087044	A3	20041104		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003226927	A1	20031027	AU 2003-226927	20030408
PRAI	DK 2002-518	A	20020409		
	DK 2002-757	A	20020516		
	WO 2003-DK232	W	20030408		

OS MARPAT 139:337786

GI



I



II

AB Title compds. I [wherein A = a linker, e.g. CHR7CONR7, CONR7, OCONR7, SO2NR7, CHR7NR7CO, NR7CONR7, hexahydro-2-oxo-pyrimidine-1,3-diyl, 2-oxoimidazolidine-1,3-diyl, 1,2,4-oxadiazolediyl, 1,3,4-oxadiazolediyl, (un)substituted imidazolediyl or 1,2,4-triazolediyl, CH=CH, OCHR7, NR7CHR7, or SCHR7; B = CH2, OCH2, O, SO2, NR7, S, NR7CH2, SCH2, CONR7, SO2NR7, CO, or CHOR7; Ar1 and Ar2 = independently (hetero)aryl; R1 and R2 = independently H, halo, CF3, OCF3, SCF3, SMe, nitrile, alkyl, alkenyl, or alkynyl; or R1 and R2 may be connected to each other to form annelated rings; R5 and R6 = independently H, halo, alkoxy, OH, (di)alkylamino, hydroxyalkyl, carboxamido, acyl(amido), CHO, nitrile, alkyl, alkenyl, alkynyl, SMe, (fluoro)alkyl, (fluoro)alkoxy, (fluoro)thioalkoxy, SO2NH2, (di)alkylaminosulfonyl, or alkylsulfonyl; more than one R5 and/or R6 may be present; Q = substituted amino; R7 = independently H, alkyl, or alkenyl; n = 1-3; and physiol. acceptable salts, complexes, solvates, and prodrugs thereof] were prepared as melanin-concentrating hormone (MCH) receptor modulators. For example, coupling of 4-aminobenzoic acid with 4-phenoxyphenyl isocyanate in DCM gave 4-[3-(4-phenoxyphenyl)ureido]benzoic acid (79%). Condensation of the acid with 2-(aminomethyl)-1-ethylpyrrolidine afforded the ureidobenzamide II (34%). In assays of [125I]-MCH binding and phosphatidylinositol turnover using transiently transfected COS-7 cells or stably transfected CHO cells expressing the human MCH-1 receptor, II exhibited activity with IC50 values of 0.25 μM and 1.3 μM, resp. Thus, I and their pharmaceutical compns. are useful in the treatment or prevention of obesity, depression, diabetes, bulimia, and other MCH receptor related disorders (no data).

IT 617246-49-8P 617246-50-1P 617246-51-2P
617246-52-3P 617246-53-4P 617246-56-7P
617246-59-0P 617246-60-3P 617246-61-4P
617246-62-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MCH receptor modulator; preparation of benzamides as MCH receptor modulators for treatment of obesity, depression, diabetes, bulimia, and related disorders)

RN 617246-49-8 CAPLUS

CN Benzamide, N-[3-(dimethylamino)propyl]-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617246-50-1 CAPLUS

CN Benzamide, 4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 617246-51-2 CAPLUS

CN Benzamide, N-[2-(4-morpholinyl)ethyl]-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617246-52-3 CAPLUS

CN Benzamide, 4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 617246-53-4 CAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617246-56-7 CAPLUS
CN Benzamide, N-[2-(dimethylamino)ethyl]-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617246-59-0 CAPLUS
CN Benzamide, N-[2-[bis(1-methylethyl)amino]ethyl]-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617246-60-3 CAPLUS
CN Benzamide, 4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 617246-61-4 CAPLUS
CN Benzamide, N-[2-(dimethylamino)ethyl]-N-methyl-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 617246-62-5 CAPLUS
CN Benzamide, N-methyl-N-[3-(4-methyl-1-piperazinyl)propyl]-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



```
=> log hold
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                        32.09     223.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                        -4.68      -4.68

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 08:06:14 ON 05 JUN 2007

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptasjl1626

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 08:06:30 ON 05 JUN 2007
FILE 'CAPLUS' ENTERED AT 08:06:30 ON 05 JUN 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                        32.09     223.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                        -4.68      -4.68

=> d his

     (FILE 'HOME' ENTERED AT 06:35:08 ON 05 JUN 2007)

     FILE 'CAPLUS' ENTERED AT 06:36:30 ON 05 JUN 2007
L1             1 S US200!-510907/APPS

     FILE 'REGISTRY' ENTERED AT 06:36:36 ON 05 JUN 2007

     FILE 'CAPLUS' ENTERED AT 06:36:39 ON 05 JUN 2007
L2               TRA L1 1- RN :      274 TERMS

     FILE 'REGISTRY' ENTERED AT 06:36:39 ON 05 JUN 2007
L3           274 SEA L2

     FILE 'REGISTRY' ENTERED AT 08:04:37 ON 05 JUN 2007
L4               STRUCTURE UPLOADED
```

```
L5              1 S L4
L6             66 S L4 SSS FULL

     FILE 'CAPLUS' ENTERED AT 08:05:48 ON 05 JUN 2007
L7              6 S L6

=> d l4
L4 HAS NO ANSWERS
L4                STR
```




```
G1 O,N


Structure attributes must be viewed using STN Express query preparation.


=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   32.56     223.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -4.68      -4.68

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 08:06:53 ON 05 JUN 2007
```

```
=> d his

     (FILE 'HOME' ENTERED AT 11:31:31 ON 05 JUN 2007)

     FILE 'CAPLUS' ENTERED AT 11:31:39 ON 05 JUN 2007
L1             0 S 7115750/PN
L2             0 S US200!-088771/APPS
L3             0 S 7115750/PN
L4             1 S US7115750/PN

     FILE 'STNGUIDE' ENTERED AT 11:35:27 ON 05 JUN 2007

     FILE 'CAPLUS' ENTERED AT 11:35:56 ON 05 JUN 2007
L5             1 S US7067506/PN
L6             2 S L4 OR L5

     FILE 'REGISTRY' ENTERED AT 11:37:12 ON 05 JUN 2007

     FILE 'CAPLUS' ENTERED AT 11:37:16 ON 05 JUN 2007
L7               TRA L6 1- RN :     1000 TERMS

     FILE 'REGISTRY' ENTERED AT 11:37:17 ON 05 JUN 2007
L8          1000 SEA L7

     FILE 'STNGUIDE' ENTERED AT 11:37:25 ON 05 JUN 2007

     FILE 'REGISTRY' ENTERED AT 11:38:36 ON 05 JUN 2007
L9               STRUCTURE UPLOADED
L10            88 S L9 SSS FULL SUB=L8

     FILE 'STNGUIDE' ENTERED AT 11:39:05 ON 05 JUN 2007

     FILE 'REGISTRY' ENTERED AT 11:41:51 ON 05 JUN 2007
L11              STRUCTURE UPLOADED
L12              STRUCTURE UPLOADED
L13            0 S L1 SUB=L10 SSS FULL

     FILE 'STNGUIDE' ENTERED AT 11:42:50 ON 05 JUN 2007

     FILE 'CAPLUS' ENTERED AT 11:43:01 ON 05 JUN 2007

     FILE 'REGISTRY' ENTERED AT 11:43:04 ON 05 JUN 2007
L14           27 S L11 SSS FULL SUB=L10
L15            0 S L12 SSS FULL SUB=L10

     FILE 'CAPLUS' ENTERED AT 11:43:50 ON 05 JUN 2007
L16            1 S L14

     FILE 'STNGUIDE' ENTERED AT 11:44:11 ON 05 JUN 2007

     FILE 'REGISTRY' ENTERED AT 11:44:32 ON 05 JUN 2007

=> d l9
L9 HAS NO ANSWERS
L9               STR
```



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

=> d l11
L11 HAS NO ANSWERS
L11 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

=> d l12
L12 HAS NO ANSWERS
L12 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

=>

=> d l16 bib abs hitstr

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:695962 CAPLUS
DN 137:232680
TI Preparation of aryl and heteroaryl urea selective Chk1 inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication
IN Keegan, Kathleen S.; Kesicki, Edward A.; Gaudino, John Joseph; Cook, Adam Wade; Cowen, Scott Douglas; Burgess, Laurence Edward
PA Icos Corporation, USA
SO PCT Int. Appl., 236 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002070494	A1	20020912	WO 2002-US6452	20020301
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2439709	A1	20020912	CA 2002-2439709	20020301
	AU 2002258451	A1	20020919	AU 2002-258451	20020301
	US 2003069284	A1	20030410	US 2002-87715	20020301
	US 7067506	B2	20060627		
	EP 1379510	A1	20040114	EP 2002-728396	20020301
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CN 1507436	A	20040623	CN 2002-809321	20020301
	JP 2004523568	T	20040805	JP 2002-569814	20020301
	BR 2002007811	A	20050201	BR 2002-7811	20020301
	NZ 527787	A	20051223	NZ 2002-527787	20020301
	ZA 2003006721	A	20040503	ZA 2003-6721	20030828
	IN 2003CN01354	A	20051125	IN 2003-CN1354	20030828
	NO 2003003858	A	20031010	NO 2003-3858	20030901
	US 2005245525	A1	20051103	US 2005-115993	20050427
PRAI	US 2001-273124P	P	20010302		
	US 2002-87715	A3	20020301		
	WO 2002-US6452	W	20020301		

OS MARPAT 137:232680
AB Aryl- and heteroaryl substituted urea compds. (W'NHC(:Y')N(R13)Z'; 1) useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. In 1, W' is a six-membered aromatic ring containing at least 2 nitrogen atoms (e.g. pyrazinyl, pyrimidinyl, pyridazinyl, 1,2,4-triazinyl, quinoxalinyl) and optionally substituted as defined in the claims, Z' is a five- or six membered aromatic or heteroarom. ring as defined in the claims, Y' is O or S. The first claim contains a much more general formula WX1C(:Y)X2Z (e.g. X1 = null, O, S, CH2, NR1; X2 = O, S, NR1) but emphasis is on 1. Methods of making the compds., and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are described. Although the methods of preparation are not claimed, about 200 example prepns. are included. N-(2-methoxy-5-methylphenyl)-N'-(2-pyrazinyl)urea and N-(4-chloro-2-methoxyphenyl)-N'-(2-pyrazinyl)urea enhanced the killing of various human cells by 5-fluorouracil from 2- to 10-fold; in HeLa cells, these same

compds. enhanced killing by irradiation 2-3 fold.

IT 457097-05-1P, 3-Methoxy-N-[3-(methylphenylamino)propyl]-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-16-4P, N-(2-Dimethylaminoethyl)-3-methoxy-N-methyl-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-18-6P, 3-Methoxy-N-(3-methylaminopropyl)-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-21-1P*** , N-(3-Dimethylaminopropyl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide ***457097-23-3P, N-(3-Dimethylaminopropyl)-3-methoxy-N-methyl-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-25-5P , 3-Methoxy-N-(3-(morpholin-4-yl)propyl)-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-27-7P, 3-Methoxy-N-[3-(4-methylpiperazin-1-yl)propyl]-4-(3-(pyrazin-2-yl)ureido)benzamide 457097-29-9P, [2-[3-Methoxy-4-(3-(pyrazin-2-yl)ureido)benzoylamino]ethyl]trimethylammonium chloride 457097-44-8P, 4-Methoxy-N-[3-(methylphenylamino)propyl]-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-46-0P, N-(2-Dimethylaminoethyl)-4-methoxy-N-methyl-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-47-1P, 4-Methoxy-N-(3-methylaminopropyl)-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-48-2P, N-(3-Dimethylaminopropyl)-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-49-3P, N-(3-Dimethylaminopropyl)-4-methoxy-N-methyl-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-50-6P , 4-Methoxy-N-[3-(4-methylpiperazin-1-yl)propyl]-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-51-7P, [2-[4-Methoxy-3-(3-(pyrazin-2-yl)ureido)benzoylamino]ethyl]trimethylammonium chloride 457097-52-8P, 4-Methoxy-N-(3-(morpholin-4-yl)propyl)-3-(3-(pyrazin-2-yl)ureido)benzamide 457097-61-9P, N-(3-Dimethylaminopropyl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-63-1P , 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-(3-(morpholin-4-yl)propyl)benzamide 457097-65-3P, N-(2-(Dimethylamino)-2-phenylethyl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457097-68-6P, N-(2-(Dimethylamino)-1-phenylethyl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457098-25-8P, 3-(3-Dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]-N-(2-(morpholin-4-yl)ethyl)benzamide 457098-27-0P, N-(2-Dimethylaminoethyl)-3-(3-dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide 457098-34-9P, 4-[3-(5-Methylpyrazin-2-yl)ureido]-N-(2-(morpholin-4-yl)ethyl)-3-(pyridin-3-ylmethoxy)benzamide 457098-36-1P, N-(2-Dimethylaminoethyl)-4-[3-(5-methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide 457099-93-3P, N-(2-Methoxy-3-((2-(4-morpholinyl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea 457099-96-6P, N-(2-Methoxy-4-((2-(4-morpholinyl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea 457099-98-8P, N-(2-Methoxy-4-((2-((methylsulfonyl)amino)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryl and heteroaryl urea selective Chk1 inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)

RN 457097-05-1 CAPLUS

CN Benzamide, 3-methoxy-N-[3-(methylphenylamino)propyl]-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-16-4 CAPLUS
CN Benzamide, N-[2-(dimethylamino)ethyl]-3-methoxy-N-methyl-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-18-6 CAPLUS
CN Benzamide, 3-methoxy-N-[3-(methylamino)propyl]-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-21-1 CAPLUS
CN Benzamide, N-[3-(dimethylamino)propyl]-3-methoxy-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-23-3 CAPLUS
CN Benzamide, N-[3-(dimethylamino)propyl]-3-methoxy-N-methyl-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-25-5 CAPLUS
CN Benzamide, 3-methoxy-N-[3-(4-morpholinyl)propyl]-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-27-7 CAPLUS
CN Benzamide, 3-methoxy-N-[3-(4-methyl-1-piperazinyl)propyl]-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-29-9 CAPLUS
CN Ethanaminium, 2-[[3-methoxy-4-[[(pyrazinylamino)carbonyl]amino]benzoyl]amino]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)



RN 457097-44-8 CAPLUS
CN Benzamide, 4-methoxy-N-[3-(methylphenylamino)propyl]-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-46-0 CAPLUS
CN Benzamide, N-[2-(dimethylamino)ethyl]-4-methoxy-N-methyl-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-47-1 CAPLUS
CN Benzamide, 4-methoxy-N-[3-(methylamino)propyl]-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-48-2 CAPLUS
CN Benzamide, N-[3-(dimethylamino)propyl]-4-methoxy-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-49-3 CAPLUS
CN Benzamide, N-[3-(dimethylamino)propyl]-4-methoxy-N-methyl-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-50-6 CAPLUS
CN Benzamide, 4-methoxy-N-[3-(4-methyl-1-piperazinyl)propyl]-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-51-7 CAPLUS
CN Ethanaminium, 2-[[4-methoxy-3-[[(pyrazinylamino)carbonyl]amino]benzoyl]amino]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)



RN 457097-52-8 CAPLUS
CN Benzamide, 4-methoxy-N-[3-(4-morpholinyl)propyl]-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-61-9 CAPLUS
CN Benzamide, N-[3-(dimethylamino)propyl]-3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-63-1 CAPLUS
CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 457097-65-3 CAPLUS
CN Benzamide, N-[2-(dimethylamino)-2-phenylethyl]-3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-68-6 CAPLUS
CN Benzamide, N-[2-(dimethylamino)-1-phenylethyl]-3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457098-25-8 CAPLUS
CN Benzamide, 3-[3-(dimethylamino)propoxy]-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 457098-27-0 CAPLUS
CN Benzamide, N-[2-(dimethylamino)ethyl]-3-[3-(dimethylamino)propoxy]-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457098-34-9 CAPLUS
CN Benzamide, 4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[2-(4-morpholinyl)ethyl]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)



RN 457098-36-1 CAPLUS
CN Benzamide, N-[2-(dimethylamino)ethyl]-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)



RN 457099-93-3 CAPLUS
CN Benzamide, 2-methoxy-N-[2-(4-morpholinyl)ethyl]-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457099-96-6 CAPLUS
CN Benzamide, 3-methoxy-N-[2-(4-morpholinyl)ethyl]-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457099-98-8 CAPLUS
CN Benzamide, 3-methoxy-N-[2-[(methylsulfonyl)amino]ethyl]-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT